Medizinische Klinik
Innere Medizin II
Hämatologie, Onkologie, klinische Immunologie und Rheumatologie

AMLSG 30-18

Randomized Phase III Study of Standard Intensive Chemotherapyversus Intensive Chemotherapy with CPX-351 in Adult Patients withNewly Diagnosed AML and Intermediate- or Adverse GeneticsAMLSG 30-18/ AML / Erstdiagnose

EudraCT-Nr.: 2018-002678-34

AMLSG 31-19

A Randomized, Placebo-Controlled Phase III Study of Induction and ConsolidationChemotherapy With Venetoclax in Adult Patients With Newly DiagnosedAcute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 / AML / MDS-B2 /Erstdiagnose

EudraCT-Nr.: 2020-004453-71

VenSwitch

Phase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML.

EudraCT-Nr.: 2022-502665-15-00

MOLIVO-1

Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients

EudraCT-Nr: 2021-006895-17

GMALL-EVOLVE

A multicentre, randomized trial in adults with de novonPhiladelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT versus TKI, blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders 

EudraCT-Nr.: 2022-000760-21

GMALL-BLIVEN

An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL) 

EudraCT-Nr.: 2021-001384-25

DZIF-Tx

Ethik- und Datenschutzkonzept des Transplantationskohorte e.V. des Deutschen Zentrums für Infektionsforschung

GRAPPA

Graft vs Host Disease Propylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG

EudraCT-Nr. 2021-000853-17

AlloRelapse MM

Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after first-line therapy

EudraCT-Nr.  2021-001005-67

HaploMUD

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trail

EudraCT-Nr. 2017-002331-41

EBMT Registry for Cellular Therapy

Datacollection on patients given hematopoietic stem cell transplantation, patients with bone marrow failures receiving immunosuppressive therapies and patients receiving Chimeric Antigen Receptor (CAR)T-cell or other immune effector cell (IEC) therapies

CD45RADLI Haplo

A multi-center phase I/II trial of memory T cell DLI infusion after transplantation of CiniMACS TCRa/b and CD19 depleted stem cell graft from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

EudraCT-Nr.  2022-001080-27

IDUNN

A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation

EudraCT-Nr. 2019-001462-15

EFC17757

A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)

EudraCT-Nr. 2023-505394-32

GMMG-HD8 

A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma.

EudraCT-Nr. 2022-000996-38

aMMbition

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC(Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma.

EudraCT-Nr.2023-505792-71

Majestec-7

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma who are either ineligible or not intended for Autologous Stem Cell Transplant as Initial Therapy (MajesTEC-7).

EudraCT-Nr. 2022-000909-28

MagnetisMM-6

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED
 PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB
 (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB
 + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE
 PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA.

EudraCT-Nr. 2021-000803-20, EU CT Nummer: 2022-500884-10-00

GMMG-HD9 

A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.

EudraCT-Nr. 2023-507402-13-00

Majestec-4

Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4, EMN30) EudraCT Number: 2021-002531-27 and Teclistamab Alone 

EudraCT Number: 2021-002531-27 and Teclistamab Alone

BMS-IM048-022

A Phase 3, Two-stage, Randomized, Multicenter, Controlled, Open-label Study
 Comparing Iberdomide Maintenance to
 Lenalidomide Maintenance Therapy after
 Autologous Stem Cell Transplantation.

EudraCT-Nr. 2022-501515-14-00

Majestec-9

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Paticipants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide.

EudraCT-Nr. 2022-000928-37

CA 057-001

A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY
 COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE
 (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd)
 IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
 (RRMM).

EurdaCT-Nr. 2021-001957-30

Linker-MM3

AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTIBCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPd), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3).

EudraCT-Nr.  2022-501396-62-00

MonumenTal-6

A Phase 3 Randomized Study Comparing Talquetamab in Comination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and investigator´s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who have received 1 to 4 Prior Lines of Therapy including an Anti-CD38 Antibody and Lenalidomide.

EudraCT-Nr. 2022-502446-27-00

Abbvie M22-947

A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma.

EudraCT-Nr. 2023-506871-88-00

MonumenTal-6

A Phase 3 Randomized Study Comparing Talquetamab in Comination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and investigator´s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who have received 1 to 4 Prior Lines of Therapy including an Anti-CD38 Antibody and Lenalidomide.

EudraCT-Nr. 2022-502446-27-00